NorthCrest Asset Management LLC Increases Stake in Hologic, Inc. (NASDAQ: HOLX)
NorthCrest Asset Management LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX – Get a rating) by 2.7% in the 1st quarter, HoldingsChannel.com reports. The company held 6,780 shares of the medical equipment supplier after acquiring an additional 180 shares during the quarter. NorthCrest Asset Management LLC’s holdings in Hologic were worth $521,000 when it last filed with the SEC.
A number of other institutional investors and hedge funds also changed their holdings in HOLX. National Asset Management Inc. increased its stake in Hologic by 5.2% during the third quarter. National Asset Management Inc. now owns 4,119 shares of the medical equipment supplier valued at $305,000 after buying 204 additional shares in the last quarter. Cetera Advisor Networks LLC bought a new position in Hologic stock in Q3 for $210,000. ArrowMark Colorado Holdings LLC increased its stake in Hologic stock by 4.3% in Q3. ArrowMark Colorado Holdings LLC now owns 1,509,253 shares of the medical equipment supplier worth $111,398,000 after buying an additional 62,757 shares last quarter. Gyon Technologies Capital Management LP increased its stake in Hologic shares by 50.6% in the third quarter. Gyon Technologies Capital Management LP now owns 19,315 shares of the medical equipment supplier worth $1,426,000 after buying 6,486 additional shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Hologic shares by 2.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,039,635 shares of the medical equipment supplier worth $150,546,000 after buying an additional 50,826 shares in the last quarter. Institutional investors and hedge funds own 92.70% of the company’s shares.
In other news, Insider John Verstreken sold 6,500 Hologic shares in a trade dated Tuesday, May 17. The stock was sold at an average price of $78.80, for a total value of $512,200.00. Following the sale, the insider now directly owns 64,191 shares of the company, valued at $5,058,250.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, available at the SEC website. Insiders own 1.54% of the shares of the company.
NASDAQ:HOLX opened at $69.78 on Wednesday. The company has a quick ratio of 2.57, a current ratio of 2.97 and a leverage ratio of 0.59. The company’s 50-day simple moving average is $73.64 and its two-hundred-day simple moving average is $73.45. The stock has a market capitalization of $17.40 billion, a PE ratio of 11.50, a P/E/G ratio of 0.89 and a beta of 1.09. Hologic, Inc. has a 52-week low of $66.26 and a 52-week high of $81.04.
Hological (NASDAQ:HOLX – Get a rating) last released its quarterly results on Wednesday, April 27. The medical equipment supplier reported EPS of $2.07 for the quarter, beating consensus analyst estimates of $1.55 by $0.52. Hologic had a return on equity of 42.26% and a net margin of 28.79%. The company posted revenue of $1.44 billion for the quarter, compared to $1.28 billion for analysts. During the same period last year, the company earned earnings per share of $2.59. Sell-side analysts expect Hologic, Inc. to post earnings per share of 5.54 for the current fiscal year.
A number of stock analysts have recently released reports on the company. Citigroup lowered its price target on Hologic from $78.00 to $75.00 in a Thursday, April 28 research note. StockNews.com began covering Hologic in a report on Thursday, March 31. They issued a “buy” rating on the stock. SVB Leerink raised its price target on Hologic to $85.00 and gave the stock an “outperform” rating in a Tuesday, May 17 report. Finally, Wells Fargo & Company downgraded Hologic from an “overweight” rating to an “equal weight” rating and lowered its stock price target from $90.00 to $75.00 in a Monday report. April 25. Four investment analysts gave the stock a hold rating and six gave the company a buy rating. According to MarketBeat, Hologic has a consensus rating of “Moderate Buy” and a consensus price target of $81.00.
About Hologic (Get a rating)
Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products for women’s health through early detection and treatment in the United States, Europe, Asia Pacific and the international. It operates through four segments: Diagnostics, Breast Health, Gynecological Surgery and Skeletal Health.
Want to see which other hedge funds hold HOLX? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Hologic, Inc. (NASDAQ:HOLX – Get a rating).
Get news and reviews for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Hologic and related companies with MarketBeat.com’s free daily email newsletter.
Comments are closed.